Saturday, January 7, 2012

PSA screening doesn't prevent cancer deaths: study

NEW YORK (Reuters Health) -

Annual screening for prostate cancer doesn't cut men's chances of dying from the disease, according to the latest results of a large screening trial.

The results support a previous report by the same researchers that found no difference in deaths seven to 10 years after the screening program started.

They are also consistent with recent draft guidelines from the U.S. Preventive Services Task Force recommending that average-risk men not undergo regular PSA screening, according to a researcher who worked on the study.

Read the full Reuters report here

PSA screening doesn't prevent cancer deaths



Friday, December 30, 2011

Milk intake in teens tied to later prostate cancer

NEW YORK (Reuters Health) -

Older Icelandic men who remember chugging a lot of milk in their teens are three times as likely to be diagnosed with advanced prostate cancer as more-moderate milk drinkers, researchers have found.

"We believe that our data are indeed solid and provide important evidence for the role of adolescence as a 'sensitive period' for prostate cancer development," Johanna Torfadottir, a nutrition scientist and a graduate student at the University of Iceland, told Reuters Health by email.

How much milk men drank had no connection to their risk of early-stage tumors, however. And intake in midlife -- the age group most other studies have focused on -- didn't seem to matter either.

"From these data alone we cannot recommend that teenage boys should chance their dietary habits," she said. "We are only looking at the risk of one disease, prostate cancer, and obviously risks of other conditions, e.g. bone health, need to be considered." "It would be premature to say that drinking milk causes prostate cancer," he told Reuters Health. "You can talk about association, but it is hard to prove causality."

Dr. Matthew Cooperberg, a urologist at the University of California, San Francisco, agreed. He added that people shouldn't be wary of drinking milk.


Read the full Reuters Health report here:

Milk intake in teens tied to later prostate cancer


Statins tied to lower risk of fatal prostate cancer

NEW YORK (Reuters Health) -

In a new study of middle-aged New Jersey men, taking cholesterol-lowering drugs was linked to a lower chance of dying from prostate cancer.

The findings don't prove that the drugs, called statins, ward off aggressive cancer. But they jibe with previous studies suggesting that getting cholesterol levels under control might help reduce the risk of life-threatening disease, researchers said.

The researchers found that men who died of prostate cancer were half as likely to have taken a statin at any time, and for any duration, than men in the "control" group.

Dr. Stephen Marcella, from the University of Medicine and Dentistry of New Jersey said "I would not tell a person if they don't have a risk of heart disease, (if) they don't have hypertension...to take a statin just to prevent lethal prostate cancer."

The evidence that's effective, he said, just isn't there yet.

And even if statins do turn out to help prevent fatal prostate cancer, researchers said, previous studies have suggested they don't lower a man's risk of getting less aggressive forms of the disease.


Read the Reuters report here:
Statins tied to lower risk of fatal prostate cancer


Friday, December 9, 2011

Study finds impotence risk higher in men taking several drugs

NEW YORK (Reuters Health) -

Men taking multiple medications for different health conditions may have a higher risk of erectile dysfunction -- a link that doesn't seem to be explained by the health problems themselves, a new study finds.

Overall, 16 percent of men on no more than two drugs reported moderate ED -- meaning they "sometimes" had trouble getting or maintaining an erection. That compared with 20 percent of men on three to five medications, a quarter of men on six to nine drugs and 31 percent of those on at least 10 drugs.

Not surprisingly, ED was more common in men who were older, heavier, smoked or had health problems like diabetes or high blood pressure. But even when the researchers accounted for that, being on multiple medications was still tied to an increased ED risk.

Senior researcher Dr. Steven J. Jacobsen said that it's possible the drugs themselves could contribute to or worsen ED -- via drug interactions, for instance. But there's no way to tell for sure from these findings.

What is clear, he stressed, is that men with erectile problems should not simply stop taking their prescriptions.


Read more details here:
Study finds impotence risk higher in men taking several drugs


Thursday, December 8, 2011

Some men can delay prostate cancer treatment: panel

CHICAGO (Reuters) -

Men with low-risk prostate cancer may wait to see if their disease progresses before treating it, an independent panel of experts convened by the U.S. National Institutes of Health (NIH) said on Wednesday.

Although this is almost 'common knowledge' these days, it's nice to see the NIH adding it's weight to the argument.


Read the full article here:
Some men can delay prostate cancer treatment


Wednesday, December 7, 2011

Prostate cancer hormonal therapy cuts deaths: report

NEW YORK (Reuters Health) -

For men with aggressive prostate cancer, hormone-targeted therapy cuts the overall risk of death, according to a new review of past studies.

It also does not increase the chance that men will die from cardiovascular disease -- which some research had suggested might be the case.

So-called androgen deprivation therapy, or ADT, has been the standard of treatment for men with more aggressive, high-risk prostate cancers. The drugs suppress the body's production of testosterone, which is known to speed cancer growth.

But they've also been linked to side effects including hot flashes, weight gain, diabetes and loss of sex drive -- and, more recently, to cardiovascular risks. One recent study linked hormone-targeted therapy to an increased risk of blood clots.

Read more here:

Prostate cancer hormonal therapy cuts deaths


Friday, December 2, 2011

Hormonal prostate cancer therapy tied to blood clots

NEW YORK (Reuters Health) -

Hormone-targeted therapy for prostate cancer may raise the risk of potentially dangerous blood clots, a large U.S. study suggests.

Analyzing data on more than 154,000 older men with prostate cancer, researchers found that those who received hormonal therapy had double the rate of blood clots in the veins, arteries or lungs compared to men not on the treatment.

Of the 58,000-plus men taking hormonal therapy, 15 percent developed a blood clot over roughly four years, versus seven percent of men who did not receive get the therapy.

A clot in the blood vessels can prove fatal if it breaks loose and travels to the lungs, heart or brain.

For men weighing their options for prostate cancer treatment, Ehdaie said the risk of blood clots -- and other side effects -- needs to be balanced against the benefits.

Other potential side effects of hormonal therapy include weight gain, bone thinning, hot flashes and erectile dysfunction.

And for many prostate cancer patients, experts say, the benefits of hormonal therapy are not clear.


More Details Here:
Hormonal prostate cancer therapy tied to blood clots